Core Viewpoint - The article discusses the ongoing activities and offerings of a real estate investment community, emphasizing its growth and member satisfaction [1]. Group 1 - The community has over 2,000 members and maintains a perfect rating of 5/5 from more than 400 reviews [1]. - A limited-time offer is available for new members to join at a significantly reduced rate [1]. - The community provides a 2-week free trial for potential members to access the entire portfolio and current top picks [1].

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - Agree Realty (ADC) is recognized as a well-managed REIT with several positive attributes, making it a quality stock for accumulation during dips [2] - The article emphasizes a defensive investment approach with a medium- to long-term horizon [2] Group 2 - The article does not provide specific financial metrics or performance data related to Agree Realty or the broader REIT market [5]

Core Insights - Agree Realty (ADC) is recognized as the highest quality name in net lease REIT coverage due to its strategic capital allocation and careful underwriting practices [1] - The investment strategy emphasizes finding undervalued companies with strong balance sheets and management teams in sectors with long-term growth potential [1] Group 1 - The company has established its reputation through intentional efforts in capital allocation and underwriting [1] - The leader of the investing group Best Of Breed Growth Stocks focuses on stocks with a high probability of delivering significant alpha compared to the S&P 500 [1] - The investment approach combines growth-oriented principles with strict valuation hurdles to enhance the margin of safety [1] Group 2 - Features of the investment group include exclusive access to high-conviction stock picks, comprehensive research reports, real-time trade alerts, macro market analysis, and a community chat for continuous engagement [1] - The analyst's strategy involves identifying companies with secular growth that appreciate over time [1]

Group 1 - The article emphasizes a quality-first investment approach, focusing on buying and owning great businesses [1] - The author has been investing since September 2017 and has a strong interest in dividend growth investing since 2009 [1] - The blog "Kody's Dividends" documents the journey towards financial independence through dividend growth investing [1] Group 2 - The author expresses a beneficial long position in the shares of ADC, indicating confidence in the investment [1] - The article is a personal opinion piece and does not represent any business relationship with companies mentioned [1]

Group 1 - The S&P 500 reached new highs on June 30th due to progress in tariff trade deals [1] - The first half of the year experienced muted gains amid increasing uncertainty regarding global trade policy [1] Group 2 - The article emphasizes the importance of quality dividend-paying companies for building investment portfolios [1] - The author aims to assist lower and middle-class workers in achieving financial independence through dividend investing [1]

Group 1: Prologis Overview - Prologis is a leading industrial REIT with a market cap of nearly $100 billion, focusing on warehouses in key transportation hubs [2][4] - The company has demonstrated resilience amid tariff concerns, with a significant 32% increase in rents on renewing leases in Q1 2025 [5] - Prologis has maintained an average annualized dividend growth rate of 11% over the past decade, with a current yield of 3.8%, which is near the high end of its 10-year yield range [5] Group 2: Agree Realty Overview - Agree Realty is a smaller net lease REIT with a market cap of $8 billion, focusing on single-tenant retail properties across the U.S. [6][7] - The company has a diversified portfolio of over 2,400 properties and offers a current dividend yield of approximately 4.2% [7] - Agree Realty has achieved a dividend growth rate exceeding 5% over the past decade, outperforming larger competitors like Realty Income [8] Group 3: Investment Appeal - Both Prologis and Agree Realty provide a combination of attractive yield and dividend growth prospects, making them appealing options for dividend investors [9] - These REITs may not suit every dividend investor, but they offer a compelling mix of income and growth potential [9]

Group 1 - Akeso, Inc. has successfully enrolled the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4, marking its first bispecific ADC to enter clinical trials [1] - AK146D1 has received approvals from the U.S. FDA, Australia's TGA, and China's NMPA to begin clinical trials, indicating strong regulatory support for the product [1] - Akeso is the only company globally with two approved cancer immunotherapy bispecific antibodies, cadonilimab and ivonescimab, establishing a strong leadership advantage in the IO+ADC space [2] Group 2 - ADC therapeutics are a key component of Akeso's "IO+ADC" 2.0 strategy, which aims to reshape the global treatment landscape and set new standards for cancer care [3] - The company emphasizes the potential of innovative bispecific ADCs like AK146D1 to unlock global clinical opportunities and enhance cancer therapies [4] - Trop2 and Nectin4 are ideal targets for ADC therapy due to their high expression in various tumor types and low expression in normal tissues, which may improve treatment efficacy [4][5] Group 3 - AK146D1 is the first bispecific ADC targeting both Trop2 and Nectin4, with preclinical studies showing strong anti-tumor activity and favorable safety profiles [5] - The development of AK146D1 holds significant potential for improving treatment outcomes for cancer patients, highlighting Akeso's commitment to advancing cancer therapies [5]

Their share prices have crashed in the past three years, even as their cash flows and dividends kept rising, and as a result, valuations are today at a near 10-year low:Your timing is perfect! We’ve just released our latest top investment picks for July 2025, and by joining today, you’ll gain immediate access to these exciting opportunities.We invest thousands of hours and over $100,000 annually into researching the most profitable investment opportunities—all to bring you real estate strategies at just a f ...

Core Points - ADC Therapeutics SA has granted options to purchase 17,000 common shares to a new employee as an inducement for employment [1][2] - The grants were approved by the Compensation Committee under the Company's Inducement Plan to motivate and reward employees [2] - The options will vest 25% on the first anniversary of the grant date and 1/48th monthly thereafter, fully vesting by the fourth anniversary [3] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs) and is focused on transforming treatment for hematologic malignancies and solid tumors [4] - The company's ADC ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [5] - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [6]

Group 1 - Samuel Smith has extensive experience in dividend stock research and investment, having served as lead analyst and Vice President at various firms [1] - He is a Professional Engineer and Project Management Professional, holding degrees in Civil Engineering & Mathematics and a Masters in Engineering with a focus on applied mathematics and machine learning [1] - Samuel leads the High Yield Investor investing group, collaborating with Jussi Askola and Paul R. Drake to balance safety, growth, yield, and value in investment strategies [2] Group 2 - High Yield Investor provides real-money core, retirement, and international portfolios, along with regular trade alerts and educational content [2] - The service includes an active chat room for investors to share insights and strategies [2]